WO2004064760A3 - Aptamer therapeutics useful in ocular pharmacotherapy - Google Patents
Aptamer therapeutics useful in ocular pharmacotherapy Download PDFInfo
- Publication number
- WO2004064760A3 WO2004064760A3 PCT/US2004/001661 US2004001661W WO2004064760A3 WO 2004064760 A3 WO2004064760 A3 WO 2004064760A3 US 2004001661 W US2004001661 W US 2004001661W WO 2004064760 A3 WO2004064760 A3 WO 2004064760A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmacotherapy
- ocular
- therapeutics useful
- aptamer therapeutics
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002513004A CA2513004A1 (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ocular pharmacotherapy |
AU2004206955A AU2004206955A1 (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ocular pharmacotherapy |
EP04704120A EP1606301A4 (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ocular pharmacotherapy |
JP2006501092A JP2006516288A (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ophthalmic drug therapy |
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44134703P | 2003-01-21 | 2003-01-21 | |
US60/441,347 | 2003-01-21 | ||
US46309503P | 2003-04-15 | 2003-04-15 | |
US60/463,095 | 2003-04-15 | ||
US46417903P | 2003-04-21 | 2003-04-21 | |
US60/464,179 | 2003-04-21 | ||
US46505503P | 2003-04-23 | 2003-04-23 | |
US60/465,055 | 2003-04-23 | ||
US46962803P | 2003-05-08 | 2003-05-08 | |
US60/469,628 | 2003-05-08 | ||
US47468003P | 2003-05-29 | 2003-05-29 | |
US60/474,680 | 2003-05-29 | ||
US49101903P | 2003-07-29 | 2003-07-29 | |
US60/491,019 | 2003-07-29 | ||
US51207103P | 2003-10-17 | 2003-10-17 | |
US60/512,071 | 2003-10-17 | ||
US53704504P | 2004-01-16 | 2004-01-16 | |
US53720104P | 2004-01-16 | 2004-01-16 | |
US60/537,045 | 2004-01-16 | ||
US60/537,201 | 2004-01-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004064760A2 WO2004064760A2 (en) | 2004-08-05 |
WO2004064760A3 true WO2004064760A3 (en) | 2005-10-27 |
Family
ID=32777434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/001661 WO2004064760A2 (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ocular pharmacotherapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1606301A4 (en) |
JP (1) | JP2006516288A (en) |
AU (1) | AU2004206955A1 (en) |
CA (1) | CA2513004A1 (en) |
WO (1) | WO2004064760A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8946184B2 (en) | 2005-02-14 | 2015-02-03 | Archemix Llc | Aptamer therapeutics useful in the treatment of complement-related disorders |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
MXPA06011965A (en) * | 2004-04-13 | 2007-04-17 | Osi Eyetech Inc | Enhanced biologically active conjugates. |
EP2436391A3 (en) * | 2004-11-02 | 2012-07-04 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
WO2006119643A1 (en) * | 2005-05-12 | 2006-11-16 | Replicor Inc. | Anti-ocular angiogenesis molecules and their uses |
RU2477137C2 (en) * | 2006-03-08 | 2013-03-10 | АРКЕМИКС Эл Эл Си | Complement-binding aptamers and c5 agents applicable for treating ocular disorders |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
JP2010100615A (en) * | 2008-09-25 | 2010-05-06 | Santen Pharmaceut Co Ltd | Prophylactic or curative agent for retinal disease including polyalkylene glycol as active ingredient |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US8993715B2 (en) * | 2009-07-06 | 2015-03-31 | Canon Kabushiki Kaisha | Labeled protein and method for obtaining the same |
JP6041373B2 (en) * | 2010-02-01 | 2016-12-07 | Necソリューションイノベータ株式会社 | Aptamer molecule that binds to TNF-α |
US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
WO2011119871A1 (en) * | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
US9410156B2 (en) | 2012-03-28 | 2016-08-09 | Somalogic, Inc. | Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions |
WO2015006734A1 (en) * | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
EP3693472A1 (en) | 2013-09-09 | 2020-08-12 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
KR20160110370A (en) * | 2013-12-04 | 2016-09-21 | 알엑스아이 파마슈티칼스 코포레이션 | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
EP3385383B1 (en) | 2015-12-04 | 2021-04-07 | Zenyaku Kogyo Co., Ltd. | Anti-il-17 aptamer having improved retention in blood |
WO2017139417A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
WO2018148333A1 (en) * | 2017-02-08 | 2018-08-16 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
WO2020120256A1 (en) * | 2018-12-11 | 2020-06-18 | Université De Strasbourg | Aptamer and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
WO2001009156A1 (en) * | 1999-07-29 | 2001-02-08 | Gilead Sciences, Inc. | HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
US20020040015A1 (en) * | 2000-02-10 | 2002-04-04 | Miller Joan W. | Methods and compositions for treating conditions of the eye |
US6458559B1 (en) * | 1998-04-22 | 2002-10-01 | Cornell Research Foundation, Inc. | Multivalent RNA aptamers and their expression in multicellular organisms |
-
2004
- 2004-01-21 CA CA002513004A patent/CA2513004A1/en not_active Abandoned
- 2004-01-21 WO PCT/US2004/001661 patent/WO2004064760A2/en active Search and Examination
- 2004-01-21 AU AU2004206955A patent/AU2004206955A1/en not_active Abandoned
- 2004-01-21 EP EP04704120A patent/EP1606301A4/en not_active Withdrawn
- 2004-01-21 JP JP2006501092A patent/JP2006516288A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6346611B1 (en) * | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6458559B1 (en) * | 1998-04-22 | 2002-10-01 | Cornell Research Foundation, Inc. | Multivalent RNA aptamers and their expression in multicellular organisms |
WO2001009156A1 (en) * | 1999-07-29 | 2001-02-08 | Gilead Sciences, Inc. | HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
US20020040015A1 (en) * | 2000-02-10 | 2002-04-04 | Miller Joan W. | Methods and compositions for treating conditions of the eye |
Non-Patent Citations (2)
Title |
---|
PIETRAS ET AL: "Inhibition of platelet-derived growth factor recetors reduces interstitial hypertentison and increases transcapillary transport in tumors", CANCER RESEARCH, vol. 61, April 2001 (2001-04-01), pages 2929 - 2934, XP002947975 * |
See also references of EP1606301A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8946184B2 (en) | 2005-02-14 | 2015-02-03 | Archemix Llc | Aptamer therapeutics useful in the treatment of complement-related disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1606301A4 (en) | 2006-06-14 |
WO2004064760A2 (en) | 2004-08-05 |
CA2513004A1 (en) | 2004-08-05 |
EP1606301A2 (en) | 2005-12-21 |
JP2006516288A (en) | 2006-06-29 |
AU2004206955A1 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004064760A3 (en) | Aptamer therapeutics useful in ocular pharmacotherapy | |
WO2007044534A3 (en) | Vegf analogs and methods of use | |
WO2005079363A3 (en) | Aptamer therapeutics useful in the treatment of complement-related disorders | |
WO2006007560A3 (en) | Targeted protein replacement for the treatment of lysosomal storage disorders | |
WO2005076998A3 (en) | Rnai therapeutics for treatment of eye neovascularization diseases | |
EP2239262A3 (en) | Fused ring heterocycle kinase modulators | |
WO2001083729A3 (en) | Vectors for ocular transduction and use thereof for genetic therapy | |
WO2005116025A3 (en) | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
WO2005000215A3 (en) | Methods for treating pain | |
WO2005001080A3 (en) | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system | |
WO2006104913A3 (en) | USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN | |
WO2007035922A3 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
WO2007011363A3 (en) | Binding domain fusion proteins | |
WO2006088888A3 (en) | Aptamer therapeutics useful in the treatment of complement-related disorders | |
WO2005123183A3 (en) | Electroporation device and method for delivery to ocular tissue | |
WO2006044860A3 (en) | Thiadiazole compounds and methods of use | |
ES2354824T3 (en) | PIRAZOLO [1,5-A] USEFUL PYRIMIDINS AS INHIBITORS OF KINASE PROTEINS. | |
WO2006124892A3 (en) | Modulators of alpha-synuclein toxicity | |
WO2005086835A3 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
WO2006018836A3 (en) | Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues | |
WO2008080045A3 (en) | Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders | |
WO2008070666A3 (en) | Compositions and methods to treat cancer with cpg rich dna and cupredoxins | |
WO2005090393A3 (en) | Multimeric protein toxins to target cells having multiple identifying characteristics | |
WO2003057856A3 (en) | Dominant negative proteins and methods thereof | |
WO2007042040A3 (en) | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2513004 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006501092 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004206955 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004206955 Country of ref document: AU Date of ref document: 20040121 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004704120 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004206955 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048048429 Country of ref document: CN |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2004704120 Country of ref document: EP |